Advisors Preferred’s Neurocrine Biosciences NBIX Stock Holding History

Advisors Preferred’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,867	Closed	-$4.2M	–	261
2025 Q4	$4.2M	Buy	+29,867	New	+$4.33M	0.68%	38

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisors Preferred's NBIX Position: Q1 2026 in Review

Advisors Preferred sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 29,867 shares — an estimated $4.2M sold.

Advisors Preferred first reported a position in NBIX in Q4 2025 and held it in 1 quarter. The position peaked at $4.2M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Advisors Preferred reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Advisors Preferred sold 29,867 Neurocrine Biosciences shares in Q1 2026, an estimated $4.2M.
Advisors Preferred first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 1 quarter.
Advisors Preferred's Neurocrine Biosciences position peaked at $4.2M in Q4 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Advisors Preferred's 13F filing for Q1 2026, filed 5 May 2026.